Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADALAT CC vs ABILIFY ASIMTUFII
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.
Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors. The active metabolite, dehydro-aripiprazole, contributes to the pharmacological activity. Abilify Asimtufii is a long-acting injectable formulation for intramuscular use.
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
Schizophrenia,Maintenance monotherapy treatment of bipolar I disorder
30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.
Recommended starting dose: 400 mg intramuscularly once monthly, with a single oral dose of 10-20 mg aripiprazole or continued oral therapy for 14 days to ensure tolerability. Maintenance dose: 300-400 mg monthly.
Terminal elimination half-life: 7-10 hours; clinical context: sustained-release formulation provides therapeutic concentrations over 24 hours with once-daily dosing, but half-life does not directly reflect drug effect duration due to slow absorption.
Terminal elimination half-life: 29-40 days (aripiprazole) and 48-63 days (dehydraripiprazole), allowing monthly dosing.
Hepatic metabolism via CYP3A4; nifedipine is converted to inactive metabolites.
Primarily hepatic via CYP2D6 and CYP3A4; active metabolite dehydro-aripiprazole is formed primarily by CYP3A4 and CYP2D6; exhibits significant interindividual variability due to CYP2D6 polymorphism.
Renal: 70-80% as metabolites, fecal: 15-20% as metabolites, biliary: minimal (<5% unchanged).
Renal (approximately 25% unchanged and 55% as metabolites), fecal (approximately 20%).
92-98% bound primarily to albumin.
>99% bound to serum albumin.
1.2-1.6 L/kg; clinical meaning: indicates extensive tissue distribution, with higher concentrations in organs such as liver and kidney, and lower in brain due to P-glycoprotein efflux.
4.9 L/kg, indicating extensive extravascular distribution.
65-90% after oral administration; absolute bioavailability of nifedipine in ADALAT CC: approximately 65% due to first-pass metabolism in liver and gut wall.
Intramuscular: 100% (as a depot suspension).
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl <30 m L/min), start at 30 mg once daily and titrate cautiously.
No dosage adjustment required for patients with renal impairment (Cr Cl ≥15 m L/min). Insufficient data for patients with end-stage renal disease (Cr Cl <15 m L/min).
For mild to moderate hepatic impairment (Child-Pugh A or B), reduce initial dose to 30 mg once daily; for severe impairment (Child-Pugh C), contraindicated or use with extreme caution.
No dosage adjustment recommended for mild to moderate hepatic impairment (Child-Pugh class A or B). Use with caution in severe hepatic impairment (Child-Pugh class C) as experience is limited.
Safety and efficacy not established; use is not recommended in pediatric patients.
Not approved for use in pediatric patients. Safety and efficacy have not been established.
Initiate at 30 mg once daily; titrate slowly due to increased risk of hypotension and higher drug exposure. Monitor closely.
Use with caution due to increased sensitivity to orthostatic hypotension and sedative effects. Consider lower starting doses (300 mg orally equivalent) but no specific dose adjustment for the injectable form is recommended.
No FDA black box warning.
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Abilify Asimtufii is not approved for the treatment of patients with dementia-related psychosis.
Beta-blocker withdrawal: taper if discontinuing; exacerbation of angina,Heart failure: use caution in patients with severe left ventricular dysfunction,Hepatic impairment: reduce dose,Peripheral edema: may occur; differentiate from worsening heart failure,Monitor blood pressure during initiation and titration
Increased mortality in elderly patients with dementia-related psychosis; cerebrovascular adverse events (e.g., stroke, transient ischemic attack) in elderly patients with dementia-related psychosis; neuroleptic malignant syndrome (NMS); tardive dyskinesia; metabolic changes (hyperglycemia/diabetes mellitus, dyslipidemia, weight gain); pathological gambling and other compulsive behaviors; orthostatic hypotension; leukopenia/neutropenia/agranulocytosis; seizures; body temperature dysregulation; dysphagia; potential for additive effects with alcohol or CNS depressants; injection site reactions; risk of extrapyramidal symptoms; suicidal thoughts/behaviors.
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concurrent use with strong CYP3A4 inducers (e.g., rifampin)
Known hypersensitivity to aripiprazole or any component of the formulation; concurrent use of strong CYP3A4 inducers (e.g., carbamazepine, rifampin)
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, raising nifedipine levels and risk of toxicity. High-fat meals may increase absorption; take consistently with respect to meals. Avoid alcohol as it may exacerbate hypotension.
Avoid grapefruit juice and grapefruit products as they may increase aripiprazole levels. Alcohol should be limited or avoided due to additive CNS depression and increased risk of sedation.
Adalat CC (nifedipine) is an extended-release formulation of nifedipine, a dihydropyridine calcium channel blocker. In animal studies, nifedipine has been associated with embryotoxicity, fetotoxicity, and teratogenicity (e.g., digital anomalies, cleft palate) at doses several times the maximum recommended human dose. In humans, data are limited but there is no clear evidence of a significant increase in major congenital malformations. First trimester exposure is not strongly associated with major defects; however, some studies suggest a possible small increase in oral clefts. Second and third trimester use may cause maternal hypotension and subsequent fetal distress (e.g., reduced uteroplacental perfusion). Use near term may theoretically inhibit labor, but nifedipine is used as a tocolytic for preterm labor. Overall, the risk is considered low; however, fetal monitoring is recommended if used in pregnancy. FDA Pregnancy Category C (prior to 2015 categorization).
Pregnancy Category C: First trimester risk of congenital malformations unknown; second/third trimester exposure may cause extrapyramidal and/or withdrawal symptoms in neonates. Advise use only if benefit outweighs risk.
Nifedipine is excreted into human breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.56 to 1.0 based on limited data. The estimated daily infant dose via milk is less than 5% of the maternal weight-adjusted dose, which is considered clinically insignificant. No adverse effects have been reported in breastfed infants. However, caution is advised, especially with high maternal doses or prolonged use. The American Academy of Pediatrics considers nifedipine compatible with breastfeeding.
Excreted in human milk; limited data. M/P ratio not established. Decision to discontinue nursing or drug based on importance of drug to mother. Use caution.
Pregnancy may alter the pharmacokinetics of nifedipine due to increased plasma volume and altered hepatic metabolism. However, specific dosing adjustments for Adalat CC in pregnancy are not well established. In clinical practice, dosing for hypertension in pregnancy (e.g., preeclampsia) often uses immediate-release nifedipine, not extended-release. For Adalat CC, the same dosing as in non-pregnant adults (30-90 mg once daily) is typically used, but titration should be cautious to avoid maternal hypotension. No formal dose adjustment is recommended, but careful monitoring and individualized titration are advised.
No recommended dose adjustments in pregnancy; consider pharmacokinetic changes (e.g., increased clearance) may require titration, but evidence lacking.
Adalat CC (nifedipine extended-release) is a dihydropyridine calcium channel blocker used primarily for hypertension. Avoid in patients with unstable angina or within 4 weeks of myocardial infarction due to reflex tachycardia risk. May cause peripheral edema, especially in higher doses; consider adding an ACE inhibitor if edema is problematic. CYP3A4 inhibitors (e.g., grapefruit juice, macrolides, azole antifungals) significantly increase nifedipine levels; avoid coadministration. Tablet shell may appear intact in stool; this is normal.
ABILIFY ASIMTUFII (aripiprazole) is a long-acting injectable suspension for intramuscular use. Administer only by a healthcare professional. Observe patient for 2 hours post-injection due to risk of post-injection delirium/sedation syndrome. Requires 3 consecutive daily doses of oral aripiprazole (10-20 mg) before initiation to confirm tolerability. Dosing: 441 mg IM monthly (equates to 400 mg aripiprazole). Do not substitute with other aripiprazole formulations on a mg-per-mg basis. Contraindicated in patients with known hypersensitivity to aripiprazole.
Swallow the tablet whole; do not crush or chew.,Do not consume grapefruit or grapefruit juice while taking this medication.,May cause dizziness or lightheadedness; avoid driving if affected.,Notify your doctor if you experience rapid heartbeat, swelling in the ankles or feet, or prolonged erections.,Take exactly as prescribed; do not skip doses or stop abruptly without consulting your doctor.
This medication is given as an injection once a month by your healthcare provider.,Do not try to inject yourself; it must be given by a healthcare professional.,After each injection, you will need to stay at the doctor's office or clinic for at least 2 hours to be monitored for any serious side effects.,You will need to take oral aripiprazole for 3 days before your first injection to see if you can tolerate the medication.,Common side effects include headache, insomnia, nausea, and injection site pain.,Seek emergency care if you have allergic reaction (hives, difficulty breathing, swelling), uncontrolled muscle movements, or thoughts of suicide.,Avoid alcohol and grapefruit juice while on this medication.,Tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.,Do not stop treatment without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADALAT CC vs ABILIFY ASIMTUFII, answered by our medical review team.
ADALAT CC is a Calcium Channel Blocker that works by Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.. ABILIFY ASIMTUFII is a Atypical antipsychotic that works by Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors. The active metabolite, dehydro-aripiprazole, contributes to the pharmacological activity. Abilify Asimtufii is a long-acting injectable formulation for intramuscular use.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADALAT CC and ABILIFY ASIMTUFII depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADALAT CC is: 30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.. The standard adult dose of ABILIFY ASIMTUFII is: Recommended starting dose: 400 mg intramuscularly once monthly, with a single oral dose of 10-20 mg aripiprazole or continued oral therapy for 14 days to ensure tolerability. Maintenance dose: 300-400 mg monthly.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADALAT CC and ABILIFY ASIMTUFII in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADALAT CC is classified as Category C. Adalat CC (nifedipine) is an extended-release formulation of nifedipine, a dihydropyridine calcium channel blocker. In animal studies, nifedipine has been associated with embryotox. ABILIFY ASIMTUFII is classified as Category C. Pregnancy Category C: First trimester risk of congenital malformations unknown; second/third trimester exposure may cause extrapyramidal and/or withdrawal symptoms in neonates. Adv. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.